查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1825321

全球脱髮症治疗市场：2025年至2030年预测

Global Alopecia Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

脱髮症治疗市场预计将从 2025 年的 51.96 亿美元增长到 2030 年的 63.48 亿美元，复合年增长率为 4.09%。

由于脱髮症，尤其是斑秃（一种导致过度脱髮症的自体免疫疾病）的盛行率不断上升，脱髮症治疗市场正在经历显着增长。不健康的饮食、久坐的生活方式、荷尔蒙变化以及包括千禧世代在内的年轻一代的压力水平上升等因素导致脱髮发病率上升。消费者对身体健康和美丽意识的不断增强进一步推动了这个市场的发展，这推动了对有效、微创治疗的需求。来自促进研究和社会意识的组织（例如美国国家斑秃基金会（NAAF））的支持也在推动市场成长。然而，治疗成本上升和新兴市场准入有限等挑战可能会阻碍市场发展。

市场驱动因素

脱髮症盛行率不断上升

脱髮症日益普遍，尤其是在年轻一代中，是市场的主要驱动力。压力、荷尔蒙失衡和生活习惯都会加剧脱髮，从而增加了对客製化治疗的需求。专注早期疗育以刺激毛囊生长，正在推动创新治疗方法的发展。早期治疗可以显着减轻症状并促进头髮生长，从而推动市场发展。

加大药物研发投入

大量的研发投入，加上新药的监管核准，正在推动市场强劲发展。製药公司正优先开发新型治疗方法，尤其是针对严重脱髮症的疗法，以满足日益增长的消费者需求。这些努力得到了强有力的临床试验和策略性收购的支持，旨在扩大其治疗组合，从而推动市场扩张。

机构支持

像NAAF这样的非营利组织透过资助研究、提高公众意识以及支持受影响群体，在脱髮症治疗市场的发展中发挥着至关重要的作用。这些倡议加速了现代药物的开发和审批，公众教育宣导活动也增加了对副作用较小的治疗方法的需求，进一步推动了市场成长。

地理视角

北美洲

由于脱髮患病率高且知名製药公司众多，以美国为首的北美预计将主导脱髮症治疗市场。该地区受益于脱髮症治疗领域巨额的医疗保健支出，以及对无痛有效解决方案日益增长的需求。生活方式的改变和压力水平的上升，尤其是在千禧世代和工薪阶层女性群体中，导致脱髮率上升，进一步催生了对创新护髮产品和治疗方法的需求。在NAAF等机构的支持下，对研发的高度重视正在促进该地区的市场成长。

由于脱髮症盛行率的上升、药物研发投入的增加以及强大的机构支持，脱髮症治疗市场预计将大幅成长。北美，尤其是美国，凭藉着高脱髮率、强劲的医疗保健支出和积极的研究计划，引领市场。诸如太阳製药 (Sun Pharma) 于 2023 年收购 Concert Pharmaceuticals 等策略性倡议，凸显了该产业对创新的关注。儘管面临治疗成本等挑战，但该市场预计将持续成长，因为它满足了消费者对美容和健康解决方案的需求，为製药公司提供了开发先进治疗方法的机会。

本报告的主要优点

  • 深刻分析：获得涵盖主要地区和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解主要企业所采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力来制定策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业来说，既有利又划算。

它有什么用途？

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（尤其是财务状况和关键发展）。

目录

第一章执行摘要

第二章市场概述

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章全球脱髮症治疗市场（按症状）

  • 介绍
  • 脱髮症
  • 全脱髮症
  • 全身性脱髮症
  • 雄性脱髮症
  • 脱髮症
  • 其他的

第六章全球脱髮症治疗市场（按药物类型）

  • 介绍
  • 口服药物
  • 外用药物
  • 注射
  • 其他的

第七章全球脱髮症治疗市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第八章竞争格局及分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章：公司简介

  • Eli Lilly and Company
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla
  • HCell Inc.
  • Daiichi Sankyo Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc

第十章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061613781

The global alopecia treatment market is expected to grow from USD 5.196 billion in 2025 to USD 6.348 billion in 2030, at a CAGR of 4.09%.

The global alopecia treatment market is experiencing significant growth, driven by the increasing prevalence of alopecia, particularly alopecia areata, an autoimmune disorder causing excessive hair loss. Factors such as unhealthy diets, sedentary lifestyles, hormonal changes, and rising stress levels among younger populations, including millennials, are contributing to the growing incidence of hair loss. The market is further propelled by heightened consumer awareness of physical well-being and aesthetic beauty, which is increasing demand for effective, minimally invasive treatments. Support from institutions like the National Alopecia Areata Foundation (NAAF) in the United States, which promotes research and public awareness, also bolsters market growth. However, challenges such as the high cost of treatments and limited accessibility in developing regions may pose constraints to market expansion.

Market Drivers

Rising Prevalence of Alopecia

The growing incidence of alopecia, particularly among younger demographics, is a primary driver of the market. Stress, hormonal imbalances, and lifestyle factors are exacerbating hair loss, prompting demand for well-designed treatments. The focus on early intervention to stimulate hair follicle growth is driving the development of innovative therapies, as early-stage treatment can significantly reduce symptoms and promote hair regrowth, fueling market growth.

Improved Investment in Drug Development

Significant investments in research and development, coupled with regulatory approvals for new drugs, are providing a strong impetus for market growth. Pharmaceutical companies are prioritizing the development of novel treatments for alopecia, particularly for severe cases, to meet rising consumer demand. These efforts are supported by robust clinical trials and strategic acquisitions aimed at enhancing treatment portfolios, driving market expansion.

Institutional Support

Non-profit organizations like the NAAF play a crucial role in advancing the alopecia treatment market by funding research, raising awareness, and supporting affected communities. These initiatives encourage the development and approval of modern medicines, while public education efforts increase demand for treatments with minimal side effects, further propelling market growth.

Geographical Outlook

North America

North America, led by the United States, is expected to dominate the alopecia treatment market due to the high prevalence of hair loss and the presence of well-established pharmaceutical companies. The region benefits from significant healthcare spending on alopecia treatments and a growing demand for painless, effective solutions. Changing lifestyles, particularly among millennials and working-class women, coupled with rising stress levels, are driving hair loss rates, further increasing the need for innovative hair care products and treatments. The strong focus on research and development, supported by organizations like the NAAF, enhances market growth in the region.

Key Developments

In March 2023, Sun Pharma acquired Concert Pharmaceuticals to advance the development of treatments for alopecia areata. This strategic acquisition aims to strengthen Sun Pharma's portfolio by promoting drugs tailored to address the needs of individuals with this condition, reflecting the industry's commitment to innovation and market expansion.

The alopecia treatment market is poised for considerable growth, driven by the rising prevalence of alopecia, increased investments in drug development, and strong institutional support. North America, particularly the U.S., leads the market due to high hair loss rates, robust healthcare spending, and active research initiatives. Strategic moves like Sun Pharma's 2023 acquisition of Concert Pharmaceuticals highlight the industry's focus on innovation. Despite challenges such as treatment costs, the market's alignment with consumer demand for aesthetic and health-focused solutions positions it for sustained expansion, offering opportunities for pharmaceutical companies to develop advanced therapies.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Condition Type

  • Alopecia Areata
  • Alopecia Totalis
  • Alopecia Universalis
  • Androgenetic Alopecia
  • Ciactricial Alopecia
  • Others

By Medication Type

  • Oral
  • Topical
  • Injectable
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL ALOPECIA TREATMENT MARKET BY CONDITION TYPE

  • 5.1. Introduction
  • 5.2. Alopecia Areata
  • 5.3. Alopecia Totalis
  • 5.4. Alopecia Universalis
  • 5.5. Androgenetic Alopecia
  • 5.6. Ciactricial Alopecia
  • 5.7. Others

6. GLOBAL ALOPECIA TREATMENT MARKET BY MEDICATION TYPE

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Topical
  • 6.4. Injectable
  • 6.5. Others

7. GLOBAL ALOPECIA TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Eli Lilly and Company
  • 9.2. Pfizer Inc.
  • 9.3. Sun Pharmaceutical Industries Ltd.
  • 9.4. Cipla
  • 9.5. HCell Inc.
  • 9.6. Daiichi Sankyo Inc.
  • 9.7. Johnson & Johnson
  • 9.8. GlaxoSmithKline plc

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key benefits for the stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations